Buy Rating Affirmed for Diamedica Therapeutics Amid Promising DM199 Trial Progress
I'm PortAI, I can summarize articles.
H.C. Wainwright analyst Matthew Caufield reaffirmed a Buy rating for Diamedica Therapeutics, citing promising progress in DM199 trials for preeclampsia and acute ischemic stroke. The company has completed Part 1a of the Phase 2 preeclampsia trial and initiated a pre-IND meeting with the FDA. Positive interim results and strategic FDA discussions support the Buy rating with a $12 price target. Cantor Fitzgerald also initiated coverage with a Buy rating and a $25 price target.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments